{"nctId":"NCT00411411","briefTitle":"Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes","startDateStruct":{"date":"2007-02"},"conditions":["Type 2 Diabetes"],"count":49,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Januvia","type":"EXPERIMENTAL","interventionNames":["Drug: Januvia"]}],"interventions":[{"name":"Januvia","otherNames":["Sitagliptin"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Type 2 diabetes diagnosed according to and in accordance with the WHO criteria\n* Metformin treatment of ≥ 1 gram\n* 7,5 % ≤ HbA1c ≤ 10%\n* Age \\> 18\n* BMI ≥ 25 kg/m2\n* Informed consent\n* Contraception, if appropriate\n\nExclusion criteria\n\n* Proliferating retinopathy\n* Uremia, end stage renal disease, diabetic nephropathy or any other cause of impaired renal function with s-creatinine \\> 130 µM and/or albuminuria (\\>300 mg/day)\n* Liver disease with ALAT and/or ASAT \\> 2 x normal value\n* Complicated coronary artery disease, NYHA group III and IV\n* Positive screening for islet cell auto antibodies and/or GAD-65 auto antibodies\n* Occurrence of type 1 diabetes in first degree relatives\n* Anaemia\n* Pregnancy and/or breast feeding\n* Treatment with medication affecting insulin secretion\n* non-compliance\n\nWithdrawal criteria\n\n* The subject may withdraw at will at any time\n* Pregnancy discovered during the trial\n* Severe illness\n* Unacceptable side effects\n* If self-measured fasting plasma glucose on three consecutive days exceeds 15 mM, the result is repeated in an immediately scheduled visit, and no treatable intercurrent cause for the hyperglycaemia can be found.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"the Relative Increase in Meal-induced Total GLP-1 Secretion","description":"Patients will be followed for 12 weeks with three meal test examinations; before treatment, after 1 week of treatment and after 12 weeks of treatment. Primary outcome is AUC GLP-1 (pM x 120 as stated).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2591","spread":"358"},{"groupId":"OG001","value":"3959","spread":"877"}]}]}]},{"type":"PRIMARY","title":"Restoration of the Insulinotropic Effect of GIP","description":"Restoration of the insulinotropic effect of GIP measured as the relative increase in GIP induced amplification of the late phase insulin secretion (AUC) response to glucose. Patients will be followed for 12 weeks with examinations after 1 and after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"3.0"},{"groupId":"OG001","value":"21.3","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"3.7"},{"groupId":"OG001","value":"30.0","spread":"6.2"}]}]}]},{"type":"SECONDARY","title":"Examination of GLP-2, Somatostatin, Glucagon, Peptide-YY and Two Glycaemic Control Parameters (HbA1c and Fasting Plasma Glucose)","description":"Secondary objectives are examination of GLP-2, somatostatin, glucagon, peptide-YY and two glycaemic control parameters (HbA1c and fasting plasma glucose). Patients will be followed for 12 weeks with three examinations; before, during and after the treatment","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}}